26.11

12.20% 2.84

After Hours: 25.70 -0.41 -1.57%

Zenas Biopharma Inc (ZBIO)

Overview News Price History Discussions Forecast

Zenas Biopharma Inc stock is traded at $26.11, with a volume of 1.67M. It is up +12.20% in the last 24 hours and up +32.00% over the past month. Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Previous Close:

$23.27

Open:

$23.27

24h Volume:

1.67M

Relative Volume:

2.32

Market Cap:

$1.40B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+24.27%

1M Performance:

+32.00%

6M Performance:

+64.21%

1Y Performance:

+262.14%

1-Day Range:

$23.01

$27.24

1-Week Range:

$20.56

$27.24

52-Week Range:

$6.11

$44.60

Zenas Biopharma Inc Stock (ZBIO) Company Profile

Name

Zenas Biopharma Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

857-271-2954

Address

852 WINTER STREET, SUITE 250, WALTHAM

Employee

130

Twitter

Next Earnings Date

Latest SEC Filings

ZBIO's Discussions on Twitter

Compare ZBIO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZBIO Zenas Biopharma Inc	26.11	1.25B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-20-25	Initiated	Wedbush	Outperform
Feb-04-25	Initiated	Wolfe Research	Outperform
Dec-16-24	Initiated	H.C. Wainwright	Buy
Nov-05-24	Initiated	Rodman & Renshaw	Buy
Oct-08-24	Initiated	Citigroup	Buy
Oct-08-24	Initiated	Guggenheim	Buy
Oct-08-24	Initiated	Jefferies	Buy
Oct-08-24	Initiated	Morgan Stanley	Overweight

View All

Zenas Biopharma Inc Stock (ZBIO) Latest News

05:19 AM

Zenas BioPharma (NASDAQ:ZBIO) Trading 13.8% HigherWhat's Next? - MarketBeat

05:19 AM

Feb 11, 2026

ZBIO: Obexelimab shows strong efficacy, safety, and commercial promise in IgG4-RD and beyond - TradingView

Feb 11, 2026

Feb 10, 2026

Zenas BioPharma’s MS drug shows 95% reduction in brain lesions By Investing.com - Investing.com Nigeria

Feb 10, 2026

HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat

Feb 10, 2026

Feb 09, 2026

Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone ... - Bluefield Daily Telegraph

Feb 09, 2026

Zenas BioPharma Announces Late-Breaking Platform - GlobeNewswire

Feb 09, 2026

Feb 08, 2026

Insider Trends: Can Zenas BioPharma Inc be the next market leaderJuly 2025 Decliners & Entry Point Confirmation Alerts - baoquankhu1.vn

Feb 08, 2026

Zenas BioPharma (ZBIO) Price Target Increased by 10.51% to 44.44 - MSN

Feb 08, 2026

Does Zenas BioPharma (ZBIO) CEO’s Million‑Dollar Share Buy Reframe Management Credibility After Recent Setbacks? - Sahm

Feb 08, 2026

Feb 05, 2026

A Look At Zenas BioPharma (ZBIO) Valuation After Positive Phase 3 INDIGO Data And CEO Share Purchase - Sahm

Feb 05, 2026

Feb 04, 2026

Commit To Purchase Zenas Biopharma At $12.50, Earn 21.9% Annualized Using Options - Nasdaq

Feb 04, 2026

Zenas Bio rises after insider purchase by CEO (ZBIO:NASDAQ) - Seeking Alpha

Feb 04, 2026

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - marketscreener.com

Feb 04, 2026

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Feb 04, 2026

Zenas BioPharma (ZBIO) Projected to Post Quarterly Earnings on Wednesday - MarketBeat

Feb 04, 2026

Feb 03, 2026

Chipmakers Recap: What is the target price for Zenas BioPharma Inc stockJuly 2025 Catalysts & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn

Feb 03, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO - Chartmill

Feb 03, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO - GlobeNewswire Inc.

Feb 03, 2026

Feb 02, 2026

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 27.4% in January - MarketBeat

Feb 02, 2026

Feb 01, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out - ACCESS Newswire

Feb 01, 2026

Published on: 2026-02-01 19:33:40 - baoquankhu1.vn

Feb 01, 2026

Jan 30, 2026

Investment Report: What are analysts price targets for ArrowMark Financial CorpWeekly Investment Summary & Daily Stock Momentum Reports - baoquankhu1.vn

Jan 30, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jan 30, 2026

Jan 28, 2026

Is Zenas BioPharma Inc.’s growth already priced in2025 Top Gainers & Safe Entry Trade Reports - mfd.ru

Jan 28, 2026